| ²é¿´: 228 | »Ø¸´: 2 | |||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | |||
huangli8200гæ (СÓÐÃûÆø)
|
[½»Á÷]
Çë½ÌÕâÌõÒâ¼û¸ÃÔõô»Ø´ð
|
||
|
In you conclusions, you state "Due to their relative low size at tens of nanometers, Fe3O4/PANI nanoparticles are capable of minimizing reticuloendothelial system (RES) (liver and spleen) uptake upon intravenous injection while having an increased affinity for molecular targets." Nanoparticles (30-50nm) in excess of the glomeri pore size in the kidney (3-5nm) will clear through the liver. Note: Ref 37 states "Enhanced uptake in liver is commonly observed with carbohydrate-modified nanoparticle preparations because of the efficient uptake mechanism into cells of the reticuloendothelial system and the large blood volume and high perfusion of the liver. лл¸÷λ³æ³æ£¬ÎÒ¸ÃÔõô»Ø¸´ÕâÌõÒâ¼û£¿ |
» ²ÂÄãϲ»¶
309Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
ÇóÉúÎïѧѧ˶µ÷¼Á¡ª¡ª364·Ö
ÒѾÓÐ3È˻ظ´
277¹¤¿ÆÇóµ÷¼Á
ÒѾÓÐ5È˻ظ´
Ò»Ö¾Ô¸ÎäÀí²ÄÁϹ¤³Ì302µ÷¼Á»·»¯»ò»¯¹¤
ÒѾÓÐ17È˻ظ´
359Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
Ò»Ö¾Ô¸¹þ¶û±õ¹¤Òµ´óѧ085600Ó¢Ò»Êý¶þ337·ÖÇóµ÷¼Á
ÒѾÓÐ11È˻ظ´
0703×Ü·Ö331Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
¿¼ÑÐÉúÎïѧ¿¼AÇø211£¬³õÊÔ322£¬¿ÆÄ¿Éú»¯ºÍÉúÎï×ۺϣ¬Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
Ò»Ö¾Ô¸±±¾©»¯¹¤085600 310·ÖÇóµ÷¼Á
ÒѾÓÐ9È˻ظ´
Ò»Ö¾Ô¸0817»¯Ñ§¹¤³ÌÓë¼¼Êõ£¬Çóµ÷¼Á
ÒѾÓÐ28È˻ظ´
huangli8200
гæ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 12
- Ìû×Ó: 77
- ÔÚÏß: 13.2Сʱ
- ³æºÅ: 678369
- ×¢²á: 2008-12-20
- רҵ: medical imaging
2Â¥2010-03-07 23:37:14
huangli8200
гæ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 12
- Ìû×Ó: 77
- ÔÚÏß: 13.2Сʱ
- ³æºÅ: 678369
- ×¢²á: 2008-12-20
- רҵ: medical imaging
3Â¥2010-03-08 11:04:09














»Ø¸´´ËÂ¥